Roivant Sciences
Price & Volume
Stats
See more52W Range | $9.89-$30.33 |
Market Cap | $20.1B |
Shares Short | 24M |
Financials
See moreRevenue (12 Mos) | $13.3M |
Revenue Growth (YoY) | -77.8% |
Gross Profit (12 Mos) | -$614.6M |
Diluted EPS | -$1.17 |
News
See moreYahoo Finance • 10 days ago
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
Yahoo Finance • 11 days ago
Immunovant falls on late-stage trial setback for TED therapy
Yahoo Finance • 11 days ago
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Yahoo Finance • 11 days ago
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
About
CEO | Mr. Matthew Gline |
Address | 50 Broadway, London, United Kingdom, SW1H 0DB |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 750 |
